Hear from our scientific founders

Entact Bio Appoints John G. Houston, Ph.D., to its Board of Directors

A veteran biopharma innovator who helped advance the first FDA-approved PROTAC drug, Dr. Houston will strengthen Entact's leadership in induced proximity therapeutics. Houston's deep experience with protein degraders will be invaluable to supporting Entact’s development of ENTAC™ medicines, which leverage the same un...

Targeted recruitment of USP15 enhances CTLA4 surface levels and restricts its degradation

Entact Bio Appoints Ruben Tommasi, Ph.D., as Chief Scientific Officer

Veteran drug developer and R&D leader with three decades of pharmaceutical and biotech experience to oversee development of targeted protein enhancement modality   Watertown, MA, September 17, 2024 – Entact Bio, a company committed to improving the lives of patients by developing precision medicines that enhance the fu...

Entact Bio Appoints Michael Gutch, Ph.D., as Chief Operating Officer

Veteran pharma and biotech executive with 20 years of operations and finance experience joins world-leading team advancing novel targeted protein enhancement modality Watertown, MA, May 29, 2024 – Entact Bio, the pioneer of precision medicines that enhance the function of beneficial proteins, today announced the appo...